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Biobanking represents a critical resource for personalized
translational medicine discovery. It is a great challenge to
establish a high quality and comprehensive tissue biobank
for cancer research. Many hospitals and clinical centers
have large archival existing formalin fixed paraffin
embedded (FFPE) tissue depository in the pathology
department along with rich history of clinical diagnosis
and long term follow up information. This is an existing
gold mine for biomarker discovery. Our laboratory has
first systematically demonstrated that unlike coding
mRNA, a class of non-coding RNA, microRNA (miRNA),
is rather stable in FFPE specimens [1]. This discovery
established the foundation of miRNA based biomarker dis-
covery using archival FFPE specimens. The superior stabi-
lity of miRNAs in archival FFPE, and serum samples
provides ideal candidates for biomarker discovery using
current tissue bank. Mounting evidence showed that post-
transcriptional and translational controls mediated by var-
ious regulatory molecules, such as RNA binding proteins
and miRNAs, are critically important in cancer. Research
involved in the translational regulation of suspected genes
in cancer has become a new frontier in recent years. Our
laboratory was first discovered that a number of miRNAs
were regulated by tumor suppressor p53 in colon cancer
[2]. Such regulatory mechanism was important in regulat-
ing cell proliferation, cycle control and cell death [3]. To
investigate the impact of miRNA in chemoresistance to
fluoropyrimidines and antifolates, we discovered that miR-
215 suppresses the expression of both thymidylate
synthase and dihydrofolate reductase [4]. In addition, the
expression of miR-215 was directly regulated by p53. The
expression of miR-215 was significantly associated with
colorectal cancer patient survival [5]. miR-140 modulates
chemosensitivity by suppressing HDAC4 expression, and
the levels of miR-140 and miR-215 were elevated in colon
cancer stem cells [6]. Our recent studies have shown that
miR-194 was directly involved in epithelial-to-mesenchy-
mal (EMT) transition, a critical event for tumor progres-
sion and metastasis. The expression of BMI-1 protein was
suppressed by miR-194 directly at the 3’-UTR region of
BMI-1 mRNA [7]. Given the significant role of miRNAs in
many aspects of tumor development such as proliferation,
cell cycle control, invasion, EMT and maintained tumor
stem cell phenotype, we remain hopeful that miRNA
based therapeutics, diagnosis and prognosis may emerge
in the near future to benefit patients.
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